symbol,price,beta,volAvg,mktCap,lastDiv,range,changes,companyName,currency,cik,isin,cusip,exchange,exchangeShortName,industry,website,description,ceo,sector,country,fullTimeEmployees,phone,address,city,state,zip,dcfDiff,dcf,image,ipoDate,defaultImage,isEtf,isActivelyTrading,isAdr,isFund
ITRM,0.7,1.60871,37912,9128700,0,0.601-1.98,-0.0001,Iterum Therapeutics plc,USD,0001659323,IE00BF3W0Q35,G6333L101,NASDAQ Capital Market,NASDAQ,Biotechnology,https://www.iterumtx.com,"Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing and commercializing anti-infectives in Ireland, Bermuda, and the United States. It is developing sulopenem, a novel anti-infective compound with oral and IV formulations that is in Phase III clinical trials for the treatment of uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections. The company was incorporated in 2015 and is headquartered in Dublin, Ireland.",Mr. Corey N. Fishman,Healthcare,IE,14,353 1 669 4820,Fitzwilliam Court,Dublin,,2,1.20312,2.41312,https://financialmodelingprep.com/image-stock/ITRM.png,2018-05-25,False,False,True,False,False
